Company intelligence / Profile preview
PanOptica
Mount Arlington, New Jersey, United Statespanopticapharma.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Commercial
01
Overview
PanOptica’s lead compound, PAN-90806, is a novel small-molecule selective VEGF receptor antagonist being developed as a topical eye drop for the treatment of neovascular age-related macular degeneration and other sight-threatening eye diseases. Clinical development has reached Phase 2 for wet AMD. The company is also developing additional assets such as PAN-90716-DES for broader eye disease indications[1][4].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships publicly disclosed; investors include SV Life Sciences and Novo A/S
Beyond the preview
Go deeper on PanOptica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PanOptica.